| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |